Alpha Tau Medical Ltd. (NASDAQ:DRTS) Stock Has Consensus Price Target of $15.40 According to Analysts

Shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS) have received an average recommendation of “Hold” from the eight ratings firms that are covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $15.40.

Several research analysts have weighed in on DRTS shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alpha Tau Medical in a research report on Thursday, October 15th. Benchmark reissued a “buy” rating on shares of Alpha Tau Medical in a research note on Thursday, July 23rd. HC Wainwright restated a “buy” rating and set a $16.00 target price on shares of Alpha Tau Medical in a report on Tuesday. Zacks Research downgraded shares of Alpha Tau Medical from a “hold” rating to a “strong sell” rating in a report on Tuesday, September 1st. Finally, Barclays upped their target price on shares of Alpha Tau Medical from $17.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, September 3rd.

Alpha Tau Medical Price Performance

NASDAQ DRTS opened at $13.48 on Thursday. The company has a quick ratio of 7.79, a current ratio of 11.09 and a debt-to-equity ratio of 0.15. Alpha Tau Medical has a 12-month low of $3.43 and a 12-month high of $15.79. The company has a market capitalization of $1.22 billion, a PE ratio of -12.96 and a beta of 1.22. The firm’s 50 day moving average is $14.44 and its 200-day moving average is $11.82.

Alpha Tau Medical (NASDAQ:DRTS) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.36). Equities research analysts anticipate that Alpha Tau Medical will post -1.05 earnings per share for the current fiscal year.

Insider Activity at Alpha Tau Medical

In related news, CFO Raphi Levy sold 17,730 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $14.00, for a total transaction of $248,220.00. Following the transaction, the chief financial officer directly owned 90,180 shares of the company’s stock, valued at approximately $1,262,520. The trade was a 16.43% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 39.50% of the company’s stock.

Institutional Trading of Alpha Tau Medical

Hedge funds have recently modified their holdings of the stock. Everhart Financial Group Inc. bought a new stake in shares of Alpha Tau Medical during the 2nd quarter worth about $126,000. Principal Financial Group Inc. acquired a new position in Alpha Tau Medical in the 1st quarter valued at about $132,000. Finally, Renaissance Technologies LLC bought a new position in Alpha Tau Medical in the 1st quarter valued at about $286,000. Institutional investors and hedge funds own 2.65% of the company’s stock.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is an Israel-based medical technology company developing targeted radiation treatments for solid tumors. Its lead technology, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), is designed to deliver highly localized alpha radiation directly within a tumor while limiting exposure to surrounding healthy tissue.

Alpha DaRT uses tiny radioactive sources, including radium-224, that are placed in or near a tumor. The sources generate short-range alpha-emitting atoms that diffuse through the tumor and damage cancer cells.